Temporal evolution of breast cancer brain metastases treatments and outcomes.

• Tác giả: Vittoria Aldegheri, Caroline Bailleux, Michele Bottosso, Anna Chiara Cattelan, Amélie Darlix, Maria Vittoria Dieci, Cristina Falci, Jean-Marc Ferrero, Carlo Alberto Giorgi, Fabio Girardi, Gaia Griguolo, Maria Cristina Guarascio, Valentina Guarneri, Severine Guiu, William Jacot, Federica Miglietta, Alessandro Parisi, Grazia Maria Vernaci, Francesca Zanghì, Christian Zurlo
• Ngôn ngữ: eng
• Ký hiệu phân loại: 355.0218 Military science
• Thông tin xuất bản: United States : NPJ breast cancer , 2025
• Bộ sưu tập: NCBI
• ID: 231660

Tóm tắt

 Brain metastases (BMs) are a common complication of advanced breast cancer (BC), and their management has significantly evolved. We evaluated the clinical impact of these changes dividing patients diagnosed with BCBMs at three Institutions according to year of BMs diagnosis: 2000-2007 (group A), 2008-2014 (group B) and 2015-2022 (group C). Stereotactic radiotherapy increased (p <
  0.001), and WBRT decreased (p = 0.010) over time. Among HER2+ BC patients, more received anti-HER2 therapy after BM diagnosis in recent years (p <
  0.011). Overall survival (OS) did not improve in the entire cohort (p = 0.260)
  however, OS improved in patients with HR-/HER2+ BC (median OS 8.7, 10.1, 23.7 months in group A, B, C, respectively
  p = 0.002). HER2-positivity, not prognostic in group A, became prognostic in group C (p <
  0.001). While therapy for patients with BCBMs significantly changed over two decades, an OS improvement was observed only in HR-/HER2+ patients, potentially due to increased availability of anti-HER2 therapies with intracranial activity.